Cathay Biotech Inc.
688065.SS
Get informed when a big investor buys or sells
+ FollowMarket Cap$27.74B
Close$
Share Statistics
| Market cap | $27.74 Billion |
|---|---|
| Enterprise Value | $19.18 Billion |
| Dividend Yield | $0.45 (1.17%) |
| Earnings per Share | $0.83 |
| Beta | 0.41 |
| Outstanding Shares | 719,187,830 |
Return
| Return on Equity | 3.55% |
|---|---|
| Return on Assets | 2.56% |
| Return on Invested Capital | 3.06% |
Valuation & Multiples
| P/E Ratio | 43.7 |
|---|---|
| PEG | 212.62 |
| Price to Sales | 9.62 |
| Price to Book Ratio | 1.28 |
| Enterprise Value to Revenue | 5.44 |
| Enterprise Value to EBIT | 28.05 |
| Enterprise Value to Net Income | 30 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 19, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.03 B
Average shareholder expectationNext Earnings Call
Expected Date
October 31, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$1.05 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Cathay Biotech Inc.
1,844 employees
CEO: Xiucai Liu Cathay Biotech Inc. specializes in biochemical products, producing and marketing bio-based polyamide, bio-based DN5, long chain dibasic acids, and biobutanol. The company's corporate base is located in Shanghai, China.